Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Durect positioned for 'market dominance' in alcoholic hepatitis, says Chardan » 08:41
11/23/20
11/23
08:41
11/23/20
08:41
DRRX

Durect

$1.71 /

-0.01 (-0.58%)

Chardan analyst Michael…

Chardan analyst Michael Morabito says Durect's call with Cheif Medical Officer Norman Sussman reaffirmed his conviction in both the likelihood of success for DUR-928 in alcoholic-associated hepatitis and expectations for "market dominance" upon commercial approval. Sussman said that upon seeing the initial Phase IIa results for DUR-928, he believed that most patients hospitalized with alcoholic-associated hepatitis are likely to receive DUR-928 as a therapy upon commercialization, Morabito tells investors in a research note. The analyst views DUR-928's opportunity in alcoholic-associated hepatitis as vast given the significant unmet patient need. He keeps a Buy rating on Durect with a $7 price target, believing DUR-928 should be able to achieve over $1B in revenue upon approval, even on a probability-adjusted basis.

ShowHide Related Items >><<
DRRX Durect
$1.71 /

-0.01 (-0.58%)

DRRX Durect
$1.71 /

-0.01 (-0.58%)

11/03/20 Chardan
Durect Covid trial update increased interest in program, says Chardan
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
DRRX Durect
$1.71 /

-0.01 (-0.58%)

DRRX Durect
$1.71 /

-0.01 (-0.58%)

DRRX Durect
$1.71 /

-0.01 (-0.58%)

Conference/Events
Durect management to meet virtually with Oppenheimer » 04:55
11/23/20
11/23
04:55
11/23/20
04:55
DRRX

Durect

$1.71 /

-0.01 (-0.58%)

Virtual Meeting to be…

Virtual Meeting to be held on November 23 hosted by Oppenheimer.

ShowHide Related Items >><<
DRRX Durect
$1.71 /

-0.01 (-0.58%)

DRRX Durect
$1.71 /

-0.01 (-0.58%)

11/03/20 Chardan
Durect Covid trial update increased interest in program, says Chardan
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
DRRX Durect
$1.71 /

-0.01 (-0.58%)

DRRX Durect
$1.71 /

-0.01 (-0.58%)

DRRX Durect
$1.71 /

-0.01 (-0.58%)

Friday
Conference/Events
Durect management to meet virtually with Oppenheimer » 12:02
11/20/20
11/20
12:02
11/20/20
12:02
DRRX

Durect

$1.71 /

-0.005 (-0.29%)

Virtual Meeting to be…

Virtual Meeting to be held on November 23 hosted by Oppenheimer.

ShowHide Related Items >><<
DRRX Durect
$1.71 /

-0.005 (-0.29%)

DRRX Durect
$1.71 /

-0.005 (-0.29%)

11/03/20 Chardan
Durect Covid trial update increased interest in program, says Chardan
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
DRRX Durect
$1.71 /

-0.005 (-0.29%)

DRRX Durect
$1.71 /

-0.005 (-0.29%)

DRRX Durect
$1.71 /

-0.005 (-0.29%)

Over a week ago
Conference/Events
American Association for Study of Liver Diseases to hold a virtual meeting » 04:55
11/16/20
11/16
04:55
11/16/20
04:55
ALBO

Albireo Pharma

$35.35 /

+0.83 (+2.40%)

, AZN

AstraZeneca

$57.37 /

+0.54 (+0.95%)

, BMY

Bristol-Myers

$63.63 /

+0.88 (+1.40%)

, CANF

Can-Fite BioPharma

$1.81 /

+ (+0.00%)

, CBAY

CymaBay

$8.19 /

+0.18 (+2.25%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DRRX

Durect

$1.79 /

+0.085 (+4.99%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXEL

Exelixis

$20.15 /

-0.08 (-0.40%)

, GSK

GlaxoSmithKline

$38.30 /

+0.55 (+1.46%)

, IVA

Inventiva

$14.01 /

+1 (+7.69%)

, MDGL

Madrigal Pharmaceuticals

$127.62 /

+2.61 (+2.09%)

, MNK

Mallinckrodt

$0.00 /

+ (+0.00%)

, MRK

Merck

$81.10 /

+1.26 (+1.58%)

, MTCH

Match Group

$131.60 /

+0.22 (+0.17%)

, NVCR

Novocure

$124.46 /

+1 (+0.81%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

AASLD 2020: The Virtual…

AASLD 2020: The Virtual Liver Meeting will be held on November 13-16. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

NVCR Novocure
$124.46 /

+1 (+0.81%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

IVA Inventiva
$14.01 /

+1 (+7.69%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

CANF Can-Fite BioPharma
$1.81 /

+ (+0.00%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

09/10/20 Cowen
Albireo Pharma price target raised to $65 from $39 at Cowen
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
09/08/20 William Blair
William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
09/08/20 Jefferies
Albireo Pharma price target raised to $79 from $50 at Jefferies
AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform at Bernstein
11/06/20 Gabelli
Bristol-Myers downgraded to Hold from Buy at Gabelli
11/05/20 BofA
BofA sees Bristol-Myers as $80 stock, 'no reason' for shares to be down
CANF Can-Fite BioPharma
$1.81 /

+ (+0.00%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

11/06/20 Raymond James
CymaBay price target raised to $12 at Raymond James after Q3 report
09/25/20 Piper Sandler
CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler
09/09/20 B. Riley Securities
CymaBay price target raised to $13 from $9 at B. Riley FBR
08/27/20 Piper Sandler
Piper Sandler 'astonished' by seladelpar's long-term benefits
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

11/03/20 Chardan
Durect Covid trial update increased interest in program, says Chardan
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
ESALY Eisai
$0.00 /

+ (+0.00%)

11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
09/08/20 Jefferies
Eisai downgraded to Hold from Buy at Jefferies
EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

11/13/20 Morgan Stanley
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/20 Liberum
GlaxoSmithKline upgraded to Buy from Hold at Liberum
10/30/20 Barclays
GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
10/27/20 Truist
AnaptysBio price target raised to $27 from $20 at Truist
IVA Inventiva
$14.01 /

+1 (+7.69%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

11/06/20 Goldman Sachs
Madrigal Pharmaceuticals price target raised to $126 from $118 at Goldman Sachs
11/06/20 Piper Sandler
Piper sees 'ideal time to buy' Madrigal Pharmaceuticals ahead of AASLD meeting
11/06/20 H.C. Wainwright
Madrigal Pharmaceuticals price target raised to $184 from $165 at H.C. Wainwright
11/05/20 Piper Sandler
Madrigal Pharmaceuticals price target lowered to $204 from $208 at Piper Sandler
MNK Mallinckrodt
$0.00 /

+ (+0.00%)

08/06/20 Citi
Mallinckrodt price target lowered to $1 from $2 at Citi
08/05/20 BMO Capital
Mallinckrodt price target lowered to $2 from $4 at BMO Capital
08/04/20 Piper Sandler
Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler
07/14/20 BMO Capital
Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital
MRK Merck
$81.10 /

+1.26 (+1.58%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
MTCH Match Group
$131.60 /

+0.22 (+0.17%)

11/10/20 Truist
Match Group price target raised to $150 from $125 at Truist
11/10/20 Deutsche Bank
Match Group price target raised to $160 from $150 at Deutsche Bank
11/09/20 Citi
Match Group price target raised to $160 from $135 at Citi
09/24/20 Jefferies
Match Group positioned to take advantage of pent up demand, says Jefferies
NVCR Novocure
$124.46 /

+1 (+0.81%)

10/30/20 Mizuho
Novocure price target raised to $150 from $84 at Mizuho
10/29/20 Piper Sandler
Novocure price target raised to $140 from $125 at Piper Sandler
10/05/20 Piper Sandler
Bristol-Myers approval removes some Novocure revenue upside, says Piper Sandler
09/23/20
Fly Intel: Top five analyst initiations
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
RHHBY Roche
$0.00 /

+ (+0.00%)

NVCR Novocure
$124.46 /

+1 (+0.81%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

  • 10
    Sep
  • 10
    Jul
  • 30
    Jan
  • 11
    Dec
RHHBY Roche
$0.00 /

+ (+0.00%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

IVA Inventiva
$14.01 /

+1 (+7.69%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

Conference/Events
American Association for Study of Liver Diseases to hold a virtual meeting » 04:55
11/15/20
11/15
04:55
11/15/20
04:55
ALBO

Albireo Pharma

$35.35 /

+0.83 (+2.40%)

, AZN

AstraZeneca

$57.37 /

+0.54 (+0.95%)

, BMY

Bristol-Myers

$63.63 /

+0.88 (+1.40%)

, CANF

Can-Fite BioPharma

$1.81 /

+ (+0.00%)

, CBAY

CymaBay

$8.19 /

+0.18 (+2.25%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DRRX

Durect

$1.79 /

+0.085 (+4.99%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXEL

Exelixis

$20.15 /

-0.08 (-0.40%)

, GSK

GlaxoSmithKline

$38.30 /

+0.55 (+1.46%)

, IVA

Inventiva

$14.01 /

+1 (+7.69%)

, MDGL

Madrigal Pharmaceuticals

$127.62 /

+2.61 (+2.09%)

, MNK

Mallinckrodt

$0.00 /

+ (+0.00%)

, MRK

Merck

$81.10 /

+1.26 (+1.58%)

, MTCH

Match Group

$131.60 /

+0.22 (+0.17%)

, NVCR

Novocure

$124.46 /

+1 (+0.81%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

AASLD 2020: The Virtual…

AASLD 2020: The Virtual Liver Meeting will be held on November 13-16. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

NVCR Novocure
$124.46 /

+1 (+0.81%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

IVA Inventiva
$14.01 /

+1 (+7.69%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

CANF Can-Fite BioPharma
$1.81 /

+ (+0.00%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

09/10/20 Cowen
Albireo Pharma price target raised to $65 from $39 at Cowen
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
09/08/20 William Blair
William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
09/08/20 Jefferies
Albireo Pharma price target raised to $79 from $50 at Jefferies
AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform at Bernstein
11/06/20 Gabelli
Bristol-Myers downgraded to Hold from Buy at Gabelli
11/05/20 BofA
BofA sees Bristol-Myers as $80 stock, 'no reason' for shares to be down
CANF Can-Fite BioPharma
$1.81 /

+ (+0.00%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

11/06/20 Raymond James
CymaBay price target raised to $12 at Raymond James after Q3 report
09/25/20 Piper Sandler
CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler
09/09/20 B. Riley Securities
CymaBay price target raised to $13 from $9 at B. Riley FBR
08/27/20 Piper Sandler
Piper Sandler 'astonished' by seladelpar's long-term benefits
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

11/03/20 Chardan
Durect Covid trial update increased interest in program, says Chardan
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
ESALY Eisai
$0.00 /

+ (+0.00%)

11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
09/08/20 Jefferies
Eisai downgraded to Hold from Buy at Jefferies
EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

11/13/20 Morgan Stanley
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/20 Liberum
GlaxoSmithKline upgraded to Buy from Hold at Liberum
10/30/20 Barclays
GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
10/27/20 Truist
AnaptysBio price target raised to $27 from $20 at Truist
IVA Inventiva
$14.01 /

+1 (+7.69%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

11/06/20 Goldman Sachs
Madrigal Pharmaceuticals price target raised to $126 from $118 at Goldman Sachs
11/06/20 Piper Sandler
Piper sees 'ideal time to buy' Madrigal Pharmaceuticals ahead of AASLD meeting
11/06/20 H.C. Wainwright
Madrigal Pharmaceuticals price target raised to $184 from $165 at H.C. Wainwright
11/05/20 Piper Sandler
Madrigal Pharmaceuticals price target lowered to $204 from $208 at Piper Sandler
MNK Mallinckrodt
$0.00 /

+ (+0.00%)

08/06/20 Citi
Mallinckrodt price target lowered to $1 from $2 at Citi
08/05/20 BMO Capital
Mallinckrodt price target lowered to $2 from $4 at BMO Capital
08/04/20 Piper Sandler
Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler
07/14/20 BMO Capital
Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital
MRK Merck
$81.10 /

+1.26 (+1.58%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
MTCH Match Group
$131.60 /

+0.22 (+0.17%)

11/10/20 Truist
Match Group price target raised to $150 from $125 at Truist
11/10/20 Deutsche Bank
Match Group price target raised to $160 from $150 at Deutsche Bank
11/09/20 Citi
Match Group price target raised to $160 from $135 at Citi
09/24/20 Jefferies
Match Group positioned to take advantage of pent up demand, says Jefferies
NVCR Novocure
$124.46 /

+1 (+0.81%)

10/30/20 Mizuho
Novocure price target raised to $150 from $84 at Mizuho
10/29/20 Piper Sandler
Novocure price target raised to $140 from $125 at Piper Sandler
10/05/20 Piper Sandler
Bristol-Myers approval removes some Novocure revenue upside, says Piper Sandler
09/23/20
Fly Intel: Top five analyst initiations
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
RHHBY Roche
$0.00 /

+ (+0.00%)

NVCR Novocure
$124.46 /

+1 (+0.81%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

  • 10
    Sep
  • 10
    Jul
  • 30
    Jan
  • 11
    Dec
RHHBY Roche
$0.00 /

+ (+0.00%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

IVA Inventiva
$14.01 /

+1 (+7.69%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

Conference/Events
American Association for Study of Liver Diseases to hold a virtual meeting » 04:55
11/14/20
11/14
04:55
11/14/20
04:55
ALBO

Albireo Pharma

$35.35 /

+0.83 (+2.40%)

, AZN

AstraZeneca

$57.37 /

+0.54 (+0.95%)

, BMY

Bristol-Myers

$63.63 /

+0.88 (+1.40%)

, CANF

Can-Fite BioPharma

$1.81 /

+ (+0.00%)

, CBAY

CymaBay

$8.19 /

+0.18 (+2.25%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DRRX

Durect

$1.79 /

+0.085 (+4.99%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXEL

Exelixis

$20.15 /

-0.08 (-0.40%)

, GSK

GlaxoSmithKline

$38.30 /

+0.55 (+1.46%)

, IVA

Inventiva

$14.01 /

+1 (+7.69%)

, MDGL

Madrigal Pharmaceuticals

$127.62 /

+2.61 (+2.09%)

, MNK

Mallinckrodt

$0.00 /

+ (+0.00%)

, MRK

Merck

$81.10 /

+1.26 (+1.58%)

, MTCH

Match Group

$131.60 /

+0.22 (+0.17%)

, NVCR

Novocure

$124.46 /

+1 (+0.81%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

AASLD 2020: The Virtual…

AASLD 2020: The Virtual Liver Meeting will be held on November 13-16. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

NVCR Novocure
$124.46 /

+1 (+0.81%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

IVA Inventiva
$14.01 /

+1 (+7.69%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

CANF Can-Fite BioPharma
$1.81 /

+ (+0.00%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

09/10/20 Cowen
Albireo Pharma price target raised to $65 from $39 at Cowen
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
09/08/20 William Blair
William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
09/08/20 Jefferies
Albireo Pharma price target raised to $79 from $50 at Jefferies
AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform at Bernstein
11/06/20 Gabelli
Bristol-Myers downgraded to Hold from Buy at Gabelli
11/05/20 BofA
BofA sees Bristol-Myers as $80 stock, 'no reason' for shares to be down
CANF Can-Fite BioPharma
$1.81 /

+ (+0.00%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

11/06/20 Raymond James
CymaBay price target raised to $12 at Raymond James after Q3 report
09/25/20 Piper Sandler
CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler
09/09/20 B. Riley Securities
CymaBay price target raised to $13 from $9 at B. Riley FBR
08/27/20 Piper Sandler
Piper Sandler 'astonished' by seladelpar's long-term benefits
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

11/03/20 Chardan
Durect Covid trial update increased interest in program, says Chardan
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
ESALY Eisai
$0.00 /

+ (+0.00%)

11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
09/08/20 Jefferies
Eisai downgraded to Hold from Buy at Jefferies
EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

11/13/20 Morgan Stanley
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/20 Liberum
GlaxoSmithKline upgraded to Buy from Hold at Liberum
10/30/20 Barclays
GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
10/27/20 Truist
AnaptysBio price target raised to $27 from $20 at Truist
IVA Inventiva
$14.01 /

+1 (+7.69%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

11/06/20 Goldman Sachs
Madrigal Pharmaceuticals price target raised to $126 from $118 at Goldman Sachs
11/06/20 Piper Sandler
Piper sees 'ideal time to buy' Madrigal Pharmaceuticals ahead of AASLD meeting
11/06/20 H.C. Wainwright
Madrigal Pharmaceuticals price target raised to $184 from $165 at H.C. Wainwright
11/05/20 Piper Sandler
Madrigal Pharmaceuticals price target lowered to $204 from $208 at Piper Sandler
MNK Mallinckrodt
$0.00 /

+ (+0.00%)

08/06/20 Citi
Mallinckrodt price target lowered to $1 from $2 at Citi
08/05/20 BMO Capital
Mallinckrodt price target lowered to $2 from $4 at BMO Capital
08/04/20 Piper Sandler
Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler
07/14/20 BMO Capital
Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital
MRK Merck
$81.10 /

+1.26 (+1.58%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
MTCH Match Group
$131.60 /

+0.22 (+0.17%)

11/10/20 Truist
Match Group price target raised to $150 from $125 at Truist
11/10/20 Deutsche Bank
Match Group price target raised to $160 from $150 at Deutsche Bank
11/09/20 Citi
Match Group price target raised to $160 from $135 at Citi
09/24/20 Jefferies
Match Group positioned to take advantage of pent up demand, says Jefferies
NVCR Novocure
$124.46 /

+1 (+0.81%)

10/30/20 Mizuho
Novocure price target raised to $150 from $84 at Mizuho
10/29/20 Piper Sandler
Novocure price target raised to $140 from $125 at Piper Sandler
10/05/20 Piper Sandler
Bristol-Myers approval removes some Novocure revenue upside, says Piper Sandler
09/23/20
Fly Intel: Top five analyst initiations
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
RHHBY Roche
$0.00 /

+ (+0.00%)

NVCR Novocure
$124.46 /

+1 (+0.81%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

  • 10
    Sep
  • 10
    Jul
  • 30
    Jan
  • 11
    Dec
RHHBY Roche
$0.00 /

+ (+0.00%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

IVA Inventiva
$14.01 /

+1 (+7.69%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

Hot Stocks
Durect reports new safety data and efficacy signals from Phase 1b NASH trial » 09:03
11/13/20
11/13
09:03
11/13/20
09:03
DRRX

Durect

$1.71 /

-0.06 (-3.40%)

Durect presented…

Durect presented additional safety data and efficacy signals from its Phase 1b clinical trial of DUR-928 in nonalcoholic steatohepatitis patients in a poster presentation at The AASLD Liver Meeting Digital Experience 2020. Data presented at The Liver Meeting further demonstrated that DUR-928 was well tolerated at all three doses with no serious adverse events reported. Additionally, in subjects with baseline triglyceride levels greater than or equal to200mg/dL, there was a 24% reduction at the end of the 4-week dosing period. The study was to evaluate safety, pharmacokinetics and signals of biological activity of DUR-928 in NASH patients with stage 1-3 fibrosis. Durect's lead drug candidate, DUR-928, is an endogenous sulfated oxysterol and an epigenetic regulator.

ShowHide Related Items >><<
DRRX Durect
$1.71 /

-0.06 (-3.40%)

DRRX Durect
$1.71 /

-0.06 (-3.40%)

11/03/20 Chardan
Durect Covid trial update increased interest in program, says Chardan
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
DRRX Durect
$1.71 /

-0.06 (-3.40%)

DRRX Durect
$1.71 /

-0.06 (-3.40%)

DRRX Durect
$1.71 /

-0.06 (-3.40%)

Conference/Events
American Association for Study of Liver Diseases to hold a virtual meeting » 08:58
11/13/20
11/13
08:58
11/13/20
08:58
ALBO

Albireo Pharma

$34.60 /

+0.46 (+1.35%)

, AZN

AstraZeneca

$56.84 /

-1.155 (-1.99%)

, BMY

Bristol-Myers

$62.74 /

-0.68 (-1.07%)

, CANF

Can-Fite BioPharma

$1.81 /

-0.225 (-11.06%)

, CBAY

CymaBay

$8.03 /

+0.07 (+0.88%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DRRX

Durect

$1.71 /

-0.06 (-3.40%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXEL

Exelixis

$20.23 /

-0.46 (-2.22%)

, GSK

GlaxoSmithKline

$37.75 /

-0.4281 (-1.12%)

, IVA

Inventiva

$13.01 /

-0.745 (-5.42%)

, MDGL

Madrigal Pharmaceuticals

$128.00 /

+1.92 (+1.52%)

, MNK

Mallinckrodt

$0.00 /

+ (+0.00%)

, MRK

Merck

$79.84 /

-1.22 (-1.51%)

, MTCH

Match Group

$131.39 /

-2.04 (-1.53%)

, NVCR

Novocure

$123.46 /

+0.9 (+0.73%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

AASLD 2020: The Virtual…

AASLD 2020: The Virtual Liver Meeting will be held on November 13-16. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

NVCR Novocure
$123.46 /

+0.9 (+0.73%)

MTCH Match Group
$131.39 /

-2.04 (-1.53%)

MRK Merck
$79.84 /

-1.22 (-1.51%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$128.00 /

+1.92 (+1.52%)

IVA Inventiva
$13.01 /

-0.745 (-5.42%)

GSK GlaxoSmithKline
$37.75 /

-0.4281 (-1.12%)

EXEL Exelixis
$20.23 /

-0.46 (-2.22%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DRRX Durect
$1.71 /

-0.06 (-3.40%)

CBAY CymaBay
$8.03 /

+0.07 (+0.88%)

CANF Can-Fite BioPharma
$1.81 /

-0.225 (-11.06%)

BMY Bristol-Myers
$62.74 /

-0.68 (-1.07%)

AZN AstraZeneca
$56.84 /

-1.155 (-1.99%)

ALBO Albireo Pharma
$34.60 /

+0.46 (+1.35%)

ALBO Albireo Pharma
$34.60 /

+0.46 (+1.35%)

09/10/20 Cowen
Albireo Pharma price target raised to $65 from $39 at Cowen
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
09/08/20 William Blair
William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
09/08/20 Jefferies
Albireo Pharma price target raised to $79 from $50 at Jefferies
AZN AstraZeneca
$56.84 /

-1.155 (-1.99%)

11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
BMY Bristol-Myers
$62.74 /

-0.68 (-1.07%)

11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform at Bernstein
11/06/20 Gabelli
Bristol-Myers downgraded to Hold from Buy at Gabelli
11/05/20 BofA
BofA sees Bristol-Myers as $80 stock, 'no reason' for shares to be down
CANF Can-Fite BioPharma
$1.81 /

-0.225 (-11.06%)

CBAY CymaBay
$8.03 /

+0.07 (+0.88%)

11/06/20 Raymond James
CymaBay price target raised to $12 at Raymond James after Q3 report
09/25/20 Piper Sandler
CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler
09/09/20 B. Riley Securities
CymaBay price target raised to $13 from $9 at B. Riley FBR
08/27/20 Piper Sandler
Piper Sandler 'astonished' by seladelpar's long-term benefits
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

DRRX Durect
$1.71 /

-0.06 (-3.40%)

11/03/20 Chardan
Durect Covid trial update increased interest in program, says Chardan
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
ESALY Eisai
$0.00 /

+ (+0.00%)

11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
09/08/20 Jefferies
Eisai downgraded to Hold from Buy at Jefferies
EXEL Exelixis
$20.23 /

-0.46 (-2.22%)

10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
GSK GlaxoSmithKline
$37.75 /

-0.4281 (-1.12%)

11/13/20 Morgan Stanley
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/20 Liberum
GlaxoSmithKline upgraded to Buy from Hold at Liberum
10/30/20 Barclays
GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
10/27/20 Truist
AnaptysBio price target raised to $27 from $20 at Truist
IVA Inventiva
$13.01 /

-0.745 (-5.42%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
MDGL Madrigal Pharmaceuticals
$128.00 /

+1.92 (+1.52%)

11/06/20 Goldman Sachs
Madrigal Pharmaceuticals price target raised to $126 from $118 at Goldman Sachs
11/06/20 Piper Sandler
Piper sees 'ideal time to buy' Madrigal Pharmaceuticals ahead of AASLD meeting
11/06/20 H.C. Wainwright
Madrigal Pharmaceuticals price target raised to $184 from $165 at H.C. Wainwright
11/05/20 Piper Sandler
Madrigal Pharmaceuticals price target lowered to $204 from $208 at Piper Sandler
MNK Mallinckrodt
$0.00 /

+ (+0.00%)

08/06/20 Citi
Mallinckrodt price target lowered to $1 from $2 at Citi
08/05/20 BMO Capital
Mallinckrodt price target lowered to $2 from $4 at BMO Capital
08/04/20 Piper Sandler
Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler
07/14/20 BMO Capital
Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital
MRK Merck
$79.84 /

-1.22 (-1.51%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
MTCH Match Group
$131.39 /

-2.04 (-1.53%)

11/10/20 Truist
Match Group price target raised to $150 from $125 at Truist
11/10/20 Deutsche Bank
Match Group price target raised to $160 from $150 at Deutsche Bank
11/09/20 Citi
Match Group price target raised to $160 from $135 at Citi
09/24/20 Jefferies
Match Group positioned to take advantage of pent up demand, says Jefferies
NVCR Novocure
$123.46 /

+0.9 (+0.73%)

10/30/20 Mizuho
Novocure price target raised to $150 from $84 at Mizuho
10/29/20 Piper Sandler
Novocure price target raised to $140 from $125 at Piper Sandler
10/05/20 Piper Sandler
Bristol-Myers approval removes some Novocure revenue upside, says Piper Sandler
09/23/20
Fly Intel: Top five analyst initiations
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
RHHBY Roche
$0.00 /

+ (+0.00%)

NVCR Novocure
$123.46 /

+0.9 (+0.73%)

MTCH Match Group
$131.39 /

-2.04 (-1.53%)

MRK Merck
$79.84 /

-1.22 (-1.51%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$128.00 /

+1.92 (+1.52%)

GSK GlaxoSmithKline
$37.75 /

-0.4281 (-1.12%)

EXEL Exelixis
$20.23 /

-0.46 (-2.22%)

DRRX Durect
$1.71 /

-0.06 (-3.40%)

CBAY CymaBay
$8.03 /

+0.07 (+0.88%)

BMY Bristol-Myers
$62.74 /

-0.68 (-1.07%)

AZN AstraZeneca
$56.84 /

-1.155 (-1.99%)

ALBO Albireo Pharma
$34.60 /

+0.46 (+1.35%)

  • 10
    Sep
  • 10
    Jul
  • 30
    Jan
  • 11
    Dec
RHHBY Roche
$0.00 /

+ (+0.00%)

MTCH Match Group
$131.39 /

-2.04 (-1.53%)

MRK Merck
$79.84 /

-1.22 (-1.51%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$37.75 /

-0.4281 (-1.12%)

BMY Bristol-Myers
$62.74 /

-0.68 (-1.07%)

AZN AstraZeneca
$56.84 /

-1.155 (-1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MTCH Match Group
$131.39 /

-2.04 (-1.53%)

MRK Merck
$79.84 /

-1.22 (-1.51%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$128.00 /

+1.92 (+1.52%)

IVA Inventiva
$13.01 /

-0.745 (-5.42%)

GSK GlaxoSmithKline
$37.75 /

-0.4281 (-1.12%)

EXEL Exelixis
$20.23 /

-0.46 (-2.22%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DRRX Durect
$1.71 /

-0.06 (-3.40%)

CBAY CymaBay
$8.03 /

+0.07 (+0.88%)

BMY Bristol-Myers
$62.74 /

-0.68 (-1.07%)

AZN AstraZeneca
$56.84 /

-1.155 (-1.99%)

ALBO Albireo Pharma
$34.60 /

+0.46 (+1.35%)

MTCH Match Group
$131.39 /

-2.04 (-1.53%)

MRK Merck
$79.84 /

-1.22 (-1.51%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$37.75 /

-0.4281 (-1.12%)

DRRX Durect
$1.71 /

-0.06 (-3.40%)

CBAY CymaBay
$8.03 /

+0.07 (+0.88%)

BMY Bristol-Myers
$62.74 /

-0.68 (-1.07%)

AZN AstraZeneca
$56.84 /

-1.155 (-1.99%)

On The Fly
Fly Intel: Pre-market Movers » 08:57
11/03/20
11/03
08:57
11/03/20
08:57
ALSK

Alaska Communications

$1.91 /

-0.01 (-0.52%)

, IEA

Infrastructure and Energy Alternatives

$7.05 /

+0.25 (+3.68%)

, W

Wayfair

$255.86 /

+7.65 (+3.08%)

, MCK

McKesson

$152.01 /

+4.495 (+3.05%)

, FOXA

Fox Corp.

$27.39 /

+0.87 (+3.28%)

, BHC

Bausch Health

$17.35 /

+0.85 (+5.15%)

, SPR

Spirit AeroSystems

$18.78 /

+0.59 (+3.24%)

, SEDG

SolarEdge

$268.15 /

+10.61 (+4.12%)

, PYPL

PayPal

$187.88 /

+1.61 (+0.86%)

, PACB

Pacific Biosciences

$13.29 /

+0.18 (+1.37%)

, MOS

Mosaic

$19.56 /

+1.06 (+5.73%)

, SYY

Sysco

$57.08 /

+1.73 (+3.13%)

, LEG

Leggett & Platt

$43.48 /

+1.77 (+4.24%)

, DRRX

Durect

$1.77 /

-0.04 (-2.21%)

, BABA

Alibaba

$310.80 /

+6.19 (+2.03%)

Check out this morning's…

ShowHide Related Items >><<
W Wayfair
$255.86 /

+7.65 (+3.08%)

SYY Sysco
$57.08 /

+1.73 (+3.13%)

SPR Spirit AeroSystems
$18.78 /

+0.59 (+3.24%)

SEDG SolarEdge
$268.15 /

+10.61 (+4.12%)

PYPL PayPal
$187.88 /

+1.61 (+0.86%)

PACB Pacific Biosciences
$13.29 /

+0.18 (+1.37%)

MOS Mosaic
$19.56 /

+1.06 (+5.73%)

MCK McKesson
$152.01 /

+4.495 (+3.05%)

LEG Leggett & Platt
$43.48 /

+1.77 (+4.24%)

IEA Infrastructure and Energy Alternatives
$7.05 /

+0.25 (+3.68%)

FOXA Fox Corp.
$27.39 /

+0.87 (+3.28%)

DRRX Durect
$1.77 /

-0.04 (-2.21%)

BHC Bausch Health
$17.35 /

+0.85 (+5.15%)

BABA Alibaba
$310.80 /

+6.19 (+2.03%)

ALSK Alaska Communications
$1.91 /

-0.01 (-0.52%)

ALSK Alaska Communications
$1.91 /

-0.01 (-0.52%)

IEA Infrastructure and Energy Alternatives
$7.05 /

+0.25 (+3.68%)

06/11/20 DA Davidson
Infrastructure and Energy Alternatives upgraded to Buy from Neutral at DA Davidson
06/11/20 DA Davidson
Infrastructure and Energy Alternatives upgraded to Buy at DA Davidson
W Wayfair
$255.86 /

+7.65 (+3.08%)

11/02/20 JPMorgan
Wayfair price target lowered to $200 from $237 at JPMorgan
10/22/20
Fly Intel: Top five analyst downgrades
10/22/20 Gordon Haskett
Wayfair downgraded to Accumulate from Buy at Gordon Haskett
10/12/20 Baird
Wayfair shipping problems likely limits near-term revenues, says Baird
MCK McKesson
$152.01 /

+4.495 (+3.05%)

11/02/20 Barclays
Barclays upgrades McKesson, gets more constructive on drug distributors
11/02/20 Barclays
McKesson upgraded to Overweight from Equal Weight at Barclays
08/04/20
Fly Intel: Top five analyst upgrades
08/04/20 JPMorgan
McKesson price target raised to $198 from $187 at JPMorgan
FOXA Fox Corp.
$27.39 /

+0.87 (+3.28%)

10/30/20 Morgan Stanley
Morgan Stanley says ad recovery lifts outlook for Fox Corp.
07/24/20 Loop Capital
Fox Corp. upgraded to Buy from Hold at Loop Capital
07/24/20 Loop Capital
Fox Corp. upgraded to Buy from Hold at Loop Capital
07/15/20 Guggenheim
Fox Corp. price target lowered to $29 from $32 at Guggenheim
BHC Bausch Health
$17.35 /

+0.85 (+5.15%)

10/26/20 Barclays
Bausch Health price target raised to $29 from $28 at Barclays
09/17/20
Fly Intel: Top five analyst upgrades
09/17/20 BofA
Bausch Health upgraded to Neutral from Underperform at BofA
08/24/20 JPMorgan
Bausch Health shares can double into separation, says JPMorgan
SPR Spirit AeroSystems
$18.78 /

+0.59 (+3.24%)

09/24/20 Wolfe Research
Spirit AeroSystems upgraded to Outperform from Peer Perform at Wolfe Research
09/10/20 Barclays
Spirit AeroSystems price target raised to $24 from $22 at Barclays
09/08/20 Morgan Stanley
Spirit AeroSystems initiated with an Underweight at Morgan Stanley
07/08/20 Bernstein
Bernstein downgrades Spirit AeroSystems on slower delivery recovery
SEDG SolarEdge
$268.15 /

+10.61 (+4.12%)

11/03/20 JPMorgan
SolarEdge weakness should be bought by long-term investors, says JPMorgan
11/03/20 Northland
SolarEdge downgraded to Underperform on valuation, slower recovery at Northland
11/03/20 Roth Capital
SolarEdge price target lowered to $280 from $300 at Roth Capital
11/03/20 Northland
SolarEdge downgraded to Underperform from Market Perform at Northland
PYPL PayPal
$187.88 /

+1.61 (+0.86%)

11/03/20 Morgan Stanley
PayPal growth potential looks even better after Q3, says Morgan Stanley
11/03/20 JPMorgan
PayPal selloff a buying opportunity, says JPMorgan
11/03/20 Baird
PayPal capitalizing on accelerating digital payment trends, says Baird
11/03/20 Baird
PayPal capitalizing on accelerating digital payment trends, says Baird
PACB Pacific Biosciences
$13.29 /

+0.18 (+1.37%)

11/03/20 Piper Sandler
Pacific Biosciences downgraded to Neutral from Overweight at Piper Sandler
10/13/20 Cantor Fitzgerald
Pacific Biosciences price target raised to $17 from $11 at Cantor Fitzgerald
10/02/20
Fly Intel: Top five analyst upgrades
10/02/20 JPMorgan
JPMorgan upgrades Pacific Biosciences to Overweight, triples target to $15
MOS Mosaic
$19.56 /

+1.06 (+5.73%)

11/03/20 Scotiabank
Mosaic downgraded to Sector Perform from Outperform at Scotiabank
10/21/20 Citi
Mosaic downgraded to Neutral from Buy at Citi
10/14/20 RBC Capital
Mosaic price target raised to $25 from $20 at RBC Capital
09/23/20 Cleveland Research
Mosaic upgraded to Buy from Neutral at Cleveland Research
SYY Sysco
$57.08 /

+1.73 (+3.13%)

10/20/20 JPMorgan
Sysco price target raised to $70 from $64 at JPMorgan
10/15/20 Jefferies
Sysco assumed with a Buy at Jefferies
09/29/20
Fly Intel: Top five analyst initiations
09/29/20 Morgan Stanley
Sysco initiated with an Equal Weight at Morgan Stanley
LEG Leggett & Platt
$43.48 /

+1.77 (+4.24%)

07/28/20 Raymond James
Leggett & Platt price target raised to $41 from $38 at Raymond James
07/08/20 Truist
Leggett & Platt price target raised to $35 from $30 at SunTrust
05/18/20 Truist
Leggett & Platt price target raised to $30 from $27 at SunTrust
05/14/20 Raymond James
Leggett & Platt double upgraded to Strong Buy at Raymond James
DRRX Durect
$1.77 /

-0.04 (-2.21%)

11/03/20 Chardan
Durect Covid trial update increased interest in program, says Chardan
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
BABA Alibaba
$310.80 /

+6.19 (+2.03%)

11/02/20 Goldman Sachs
Alibaba price target raised to $360 from $350 at Goldman Sachs
11/02/20 KeyBanc
Report confirms Farfetch best positioned luxury marketplace, says KeyBanc
10/26/20 Oppenheimer
Alibaba price target raised to $335 from $325 at Oppenheimer
10/20/20 Barclays
Alibaba price target raised to $360 from $320 at Barclays
W Wayfair
$255.86 /

+7.65 (+3.08%)

SYY Sysco
$57.08 /

+1.73 (+3.13%)

SPR Spirit AeroSystems
$18.78 /

+0.59 (+3.24%)

SEDG SolarEdge
$268.15 /

+10.61 (+4.12%)

PYPL PayPal
$187.88 /

+1.61 (+0.86%)

PACB Pacific Biosciences
$13.29 /

+0.18 (+1.37%)

MOS Mosaic
$19.56 /

+1.06 (+5.73%)

MCK McKesson
$152.01 /

+4.495 (+3.05%)

LEG Leggett & Platt
$43.48 /

+1.77 (+4.24%)

FOXA Fox Corp.
$27.39 /

+0.87 (+3.28%)

DRRX Durect
$1.77 /

-0.04 (-2.21%)

BHC Bausch Health
$17.35 /

+0.85 (+5.15%)

BABA Alibaba
$310.80 /

+6.19 (+2.03%)

  • 12
    Aug
W Wayfair
$255.86 /

+7.65 (+3.08%)

SYY Sysco
$57.08 /

+1.73 (+3.13%)

SPR Spirit AeroSystems
$18.78 /

+0.59 (+3.24%)

PYPL PayPal
$187.88 /

+1.61 (+0.86%)

PACB Pacific Biosciences
$13.29 /

+0.18 (+1.37%)

MCK McKesson
$152.01 /

+4.495 (+3.05%)

FOXA Fox Corp.
$27.39 /

+0.87 (+3.28%)

BABA Alibaba
$310.80 /

+6.19 (+2.03%)

W Wayfair
$255.86 /

+7.65 (+3.08%)

SYY Sysco
$57.08 /

+1.73 (+3.13%)

SPR Spirit AeroSystems
$18.78 /

+0.59 (+3.24%)

SEDG SolarEdge
$268.15 /

+10.61 (+4.12%)

PYPL PayPal
$187.88 /

+1.61 (+0.86%)

PACB Pacific Biosciences
$13.29 /

+0.18 (+1.37%)

MOS Mosaic
$19.56 /

+1.06 (+5.73%)

MCK McKesson
$152.01 /

+4.495 (+3.05%)

LEG Leggett & Platt
$43.48 /

+1.77 (+4.24%)

FOXA Fox Corp.
$27.39 /

+0.87 (+3.28%)

DRRX Durect
$1.77 /

-0.04 (-2.21%)

BHC Bausch Health
$17.35 /

+0.85 (+5.15%)

BABA Alibaba
$310.80 /

+6.19 (+2.03%)

W Wayfair
$255.86 /

+7.65 (+3.08%)

SYY Sysco
$57.08 /

+1.73 (+3.13%)

SPR Spirit AeroSystems
$18.78 /

+0.59 (+3.24%)

SEDG SolarEdge
$268.15 /

+10.61 (+4.12%)

PYPL PayPal
$187.88 /

+1.61 (+0.86%)

PACB Pacific Biosciences
$13.29 /

+0.18 (+1.37%)

MOS Mosaic
$19.56 /

+1.06 (+5.73%)

MCK McKesson
$152.01 /

+4.495 (+3.05%)

LEG Leggett & Platt
$43.48 /

+1.77 (+4.24%)

FOXA Fox Corp.
$27.39 /

+0.87 (+3.28%)

DRRX Durect
$1.77 /

-0.04 (-2.21%)

BHC Bausch Health
$17.35 /

+0.85 (+5.15%)

BABA Alibaba
$310.80 /

+6.19 (+2.03%)

Recommendations
Durect Covid trial update increased interest in program, says Chardan » 08:48
11/03/20
11/03
08:48
11/03/20
08:48
DRRX

Durect

$1.77 /

-0.04 (-2.21%)

Chardan analyst Michael…

Chardan analyst Michael Morabito keeps a Buy rating on Durect with a $7 price target following the company's "unsurprising" Q3 results. Management confirmed that it has recruited several clinical sites already and will begin dosing alcoholic hepatitis patients imminently, with plans to expand to roughly 40-45 sites, Morabito tells investors in a research note. Further, the analyst says the COVID-19 trial update increased his interest in the COVID program for DUR-928.

ShowHide Related Items >><<
DRRX Durect
$1.77 /

-0.04 (-2.21%)

DRRX Durect
$1.77 /

-0.04 (-2.21%)

10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
10/12/20 Roth Capital
Durect initiated with a Buy at Roth Capital
DRRX Durect
$1.77 /

-0.04 (-2.21%)

DRRX Durect
$1.77 /

-0.04 (-2.21%)

DRRX Durect
$1.77 /

-0.04 (-2.21%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.